Advertisement

Impact of direct-acting oral anticoagulants and warfarin on postendoscopic GI bleeding and thromboembolic events in patients undergoing elective endoscopy

Published:February 29, 2020DOI:https://doi.org/10.1016/j.gie.2020.02.038

      Background and Aims

      An increasing number of patients are undergoing GI endoscopic procedures with active prescriptions for direct oral anticoagulants (DOACs). DOACs have been associated with a higher risk of GI bleeding (GIB) compared with warfarin. Our aims were to compare the risk of postendoscopic GIB and thromboembolic (TE) events among patients on DOACs versus warfarin.

      Methods

      We conducted a retrospective cohort study of patients aged 18 years or older in a large integrated health care system in Southern California, who had undergone an outpatient GI endoscopic procedure and were taking a DOAC or warfarin between January 1, 2013, and October 1, 2019. We compared bleeding and thrombosis risk in the 30 days after the endoscopic procedure between the warfarin and DOAC groups using multivariate logistic regression analysis adjusted for covariates.

      Results

      Between January 1, 2013, and October 1, 2019, we identified 6765 outpatient GI endoscopic procedures in which patients received preprocedure prescriptions for either a DOAC (1587) or warfarin (5178). Overall, there was no significant difference in postprocedure GIB (odds ratio [OR], 1.165; 95% confidence interval [CI], 0.88-1.55; P = .291) or TE (OR, 0.929; 95% CI, 0.64-1.35; P = .703) between the DOAC and warfarin groups). Subgroup analysis revealed a higher risk of GIB associated with DOAC specifically with EGD procedures (OR, 1.8; 95% CI, 1.15-2.83; P = .011).

      Conclusions

      There was no significant difference in the overall postendoscopic risk of GIB and TE events among patients with preprocedure use of DOACs compared with patients on warfarin. There may be a higher risk of GIB in patients taking DOACs and undergoing EGD.

      Graphical abstract

      Abbreviations:

      CI (confidence interval), DOAC (direct oral anticoagulant), GIB (gastrointestinal bleeding), KPSC (Kaiser Permanente Southern California), OR (odds ratio), PEG (percutaneous endoscopic gastrostomy), TE (thromboembolic)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Peery A.F.
        • Dellon E.S.
        • Lund J.
        • et al.
        Burden of gastrointestinal disease in the United States: 2012 update.
        Gastroenterology. 2012; 143: 1179-1187.e3
        • Zhu J.
        • Alexander G.C.
        • Nazarian S.
        • et al.
        Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017.
        Pharmacother J Hum Pharmacol Drug Ther. 2018; 38: 907-920
        • Fohtung R.B.
        • Novak E.
        • Rich M.W.
        Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults.
        J Am Geriatr Soc. 2017; 65: 2405-2412
        • Tomaselli G.F.
        • Mahaffey K.W.
        • Cuker A.
        • et al.
        2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants.
        J Am Coll Cardiol. 2017; 70: 3042-3067
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation.
        J Am Coll Cardiol. 2019; 74: 104-132
        • Xian Y.
        • Xu H.
        • O’Brien E.C.
        • et al.
        Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke.
        JAMA Neurol. Epub. 2019 July 22;
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Okumura Y.
        • Yokoyama K.
        • Matsumoto N.
        • et al.
        Patient satisfaction with direct oral anticoagulants and warfarin.
        Int Heart J. 2018; 59: 1266-1274
        • Holster I.L.
        • Valkhoff V.E.
        • Kuipers E.J.
        • et al.
        New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.
        Gastroenterology. 2013; 145: 105-112.e15
        • Miller C.S.
        • Dorreen A.
        • Martel M.
        • et al.
        Risk of gastrointestinal bleeding in patients taking non–vitamin k antagonist oral anticoagulants: a systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2017; 15: 1674-1683.e3
        • Desai J.
        • Granger C.B.
        • Weitz J.I.
        • et al.
        Novel oral anticoagulants in gastroenterology practice.
        Gastrointest Endosc. 2013; 78: 227-239
        • Deutsch D.
        • Boustière C.
        • Ferrari E.
        • et al.
        Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.
        Therap Adv Gastroenterol. 2017; 10: 495-505
        • Acosta R.D.
        • Abraham N.S.
        • Chandrasekhara V.
        • et al.
        The management of antithrombotic agents for patients undergoing GI endoscopy.
        Gastrointest Endosc. 2016; 83: 3-16
        • Flaker G.C.
        • Theriot P.
        • Binder L.G.
        • et al.
        Management of periprocedural anticoagulation: a survey of contemporary practice.
        J Am Coll Cardiol. 2016; 68: 217-226
        • Slivnick J.A.
        • Yeow R.Y.
        • McMahon C.
        • et al.
        Current trends in anticoagulation bridging for patients with chronic atrial fibrillation on warfarin undergoing endoscopy.
        Am J Cardiol. 2018; 121: 1548-1551
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Kolb J.M.
        • Flack K.F.
        • Chatterjee-Murphy P.
        • et al.
        Locations and mucosal lesions responsible for major gastrointestinal bleeding in patients on warfarin or dabigatran.
        Dig Dis Sci. 2018; 63: 1878-1889
        • Nagata N.
        • Yasunaga H.
        • Matsui H.
        • et al.
        Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis.
        Gut. 2017; : 1805-1812
        • Yanagisawa N.
        • Nagata N.
        • Watanabe K.
        • et al.
        Post-polypectomy bleeding and thromboembolism risks associated with warfarin vs direct oral anticoagulants.
        World J Gastroenterol. 2018; 24: 1540-1549
        • Radaelli F.
        • Fuccio L.
        • Paggi S.
        • et al.
        Periendoscopic management of direct oral anticoagulants: a prospective cohort study.
        Gut. 2018; 28: 1914-1922
        • Heublein V.
        • Pannach S.
        • Daschkow K.
        • et al.
        Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry.
        J Gastroenterol. 2018; 53: 236-246
        • Veitch A.M.
        • Vanbiervliet G.
        • Gershlick A.H.
        • et al.
        Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.
        Gut. 2016; 65: 374-389

      Linked Article

      • Warfarin should be switched to heparin bridging for patients with high thromboembolic risk
        Gastrointestinal EndoscopyVol. 92Issue 3
        • Preview
          We read with great interest the article by Tien et al.1 The authors presented some new findings indicating that direct oral anticoagulants (DOAC) did not increase the risk of postendoscopic GI bleeding and thromboembolic (TE) events when compared with warfarin, as per the data of a large integrated healthcare system. Endoscopists need to continually strike a balance between bleeding and thromboembolism in patients taking anticoagulants. Notably, this research provided evidence for endoscopists regarding anticoagulant management in the preoperative stage, especially for DOAC.
        • Full-Text
        • PDF